Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cenix BioScience Expands Operations to U.S.

Published: Friday, March 02, 2012
Last Updated: Friday, March 02, 2012
Bookmark and Share
Company establishes new subsidiary named Cenix BioScience USA in Minnesota.

Cenix BioScience has announced that it is expanding its operations by establishing a new subsidiary in the United States.

The new corporation, named Cenix BioScience USA, Inc., is now being set-up in the Minneapolis/St. Paul area of Minnesota as a wholly owned subsidiary of its German parent.

The new operation will gradually integrate top management, business development and marketing functions, as well as major new R&D capabilities to extend and complement those long established in Dresden, Germany, and recently added in Beerse, Belgium.

As such, this important new step in the company’s ongoing growth and diversification will further broaden the scope of Cenix activities, while also facilitating closer interactions with North American partners from coast to coast.

“Through our many activities with North American partners over the years, we have often been asked when we would expand Cenix across the Atlantic, and so, that time has finally come,” said Dr. Christophe Echeverri, CEO/CSO of Cenix.

Dr. Echeverri continued, “We are particularly excited to have the opportunity to combine our existing expertise, which we have built-up and refined over 12 years of intensive discovery work alongside many top industrial and academic partners, with the world-class know-how, cutting-edge capabilities and deep resources available in the Twin Cities region and beyond.”

Cenix will continue to strengthen its leading expertise in advanced applications of RNAi and miRNA modulation combined with high content predictive pharmacology, helping its clients, and particularly large pharmaceutical companies with ever-tighter budgets, in refocusing their discovery efforts to drive more cost-effective, innovative and reliable high-impact R&D.

Dr. Echeverri, continuing in his duties as CEO/CSO of Cenix globally, will now be based primarily in Minneapolis, where he is leading the design and build-up of Cenix USA.

This will include a brand new team, as existing Cenix operations in Germany and Belgium will continue largely unchanged, with Dr. Birte Sönnichsen, long-time Cenix COO, taking on Co-Managing Director duties for the Dresden operation.

“We’ve talked about doing this for a long time, so with RNAi and miRNA modulation having become such central contributors to virtually all discovery pipelines, we now have many possible opportunities to launch exciting new diversification initiatives.” noted Dr. Echeverri.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Company will undertake a target discovery project for an undisclosed disease indication.
Tuesday, May 06, 2014
Cenix BioScience Joins EU FP7 Consortium for Discovery of miRNA Medicines
Company has joined an EU-funded consortium focused on the discovery of microRNA medicines in the area of cardiac and inflammatory metabolic diseases.
Wednesday, August 14, 2013
Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH, announced it has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Thursday, November 17, 2011
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
Collaboration and Technology License Agreement to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARE™.
Thursday, May 05, 2011
Cenix BioScience Joins EU FP7 Consortium
Consortium focused on improving the in vivo use of siRNA technology in the area of respiratory and inflammatory diseases.
Wednesday, March 30, 2011
Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
The new company accelerates the development of the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi.
Saturday, January 15, 2011
Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.
Friday, June 26, 2009
Cenix BioScience Signs Multi-Project Research Agreement with AstraZeneca
The agreement expands relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.
Tuesday, June 16, 2009
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
The research agreement comprises functional screens in human cell lines using InteRNA’s proprietary library of miRNAs.
Tuesday, November 18, 2008
Scientific News
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Curing Disease by Repairing Faulty Genes
New delivery method boosts efficiency of CRISPR genome-editing system.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!